Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 4.2 %

NASDAQ:AKTX opened at $2.84 on Wednesday. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $5.50. The firm has a 50-day moving average price of $1.77 and a two-hundred day moving average price of $2.22.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC grew its stake in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 87,628 shares of the biopharmaceutical company’s stock after acquiring an additional 28,511 shares during the period. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent reporting period. 5.06% of the stock is currently owned by hedge funds and other institutional investors.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.